On Thursday, Shares of The Western Union Company (NYSE:WU), lost -6.87% to $18.99.
The Western Union Company, declared that President and CEO Hikmet Ersek will host a webcast and conference call to talk about second quarter 2015 results on July 30, 2015 at 4:30 p.m. Eastern time. Raj Agrawal, Executive Vice President and CFO, will also take part on the call. A press release highlighting the financial results will be issued at about 4:00 p.m. Eastern time the same day.
The Western Union Company provides money movement and payment services worldwide. The company operates in three segments: Consumer-to-Consumer, Consumer-to-Business, and Business Solutions. The Consumer-to-Consumer segment offers cash money transfer services involving walk-in agent locations.
Shares of Tesla Motors, Inc. (NASDAQ:TSLA), inclined 4.04% to $280.02, during its last trading session.
Tesla Motors, declared 11,507 Model S deliveries for Q2 2015. This was a new company record for the most cars delivered in a quarter and represents an approximate 52% enhance over Q2 last year.
There may be small changes to this delivery count (usually well under 1%), as Tesla only counts a delivery if it is transferred to the end customer and all paperwork is correct.
Also, this is only one measure of our financial performance and should not be relied on as an indicator of our quarterly financial results, which depend on a variety of factors, counting the cost of sales, foreign exchange movements and mix of directly leased vehicles.
Tesla Motors, Inc. designs, develops, manufactures, and sells electric vehicles, electric vehicle powertrain components, and stationary energy storage systems in the United States, China, Norway, and internationally. It also provides development services to develop electric vehicle powertrain components and systems for other automotive manufacturers.
Finally, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), ended its last trade with -4.02% gain, and closed at $131.26.
Vertex Pharmaceuticals Incorporated, declared that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018.
“Dr. Bhatia is a leading physician scientist and medical researcher who brings a wealth of expertise to our board,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. “Her extensive experience in the field of biomedical engineering and in-depth understanding on the use of advanced technologies in medical research will provide valuable insights to our board and our company as we advance key research and development programs.”
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
